Theraclion   Report issue

For profit Phase 1
Founded: Malakoff France (2004)
Status: No NME R&D (2004)

Organization Overview

First Clinical Trial
2019
NCT04116320
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Theraclion

Active Ingredients

Drugs in Phase 1 Trials (1)

imiquimod (aldara) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Merkel Cell (Phase 1)

Carcinoma, Squamous Cell (Phase 1)

Lung Neoplasms (Phase 1)

Microsatellite Instability (Phase 1)

Neoplasms, Squamous Cell (Phase 1)

Small Cell Lung Carcinoma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1